Produktübersicht
- Written by Super User
- font size
- 483099 comments
483099 comments
-
Hi there, its fastidious post on the topic of media print, we all be aware of media is a impressive source of information.
-
Hi there, You have done an incredible job. I will certainly digg it
and personally recommend to my friends. I'm sure they'll be benefited
from this site. -
Very great post. I just stumbled upon your weblog and wished to mention that I have truly enjoyed surfing around your blog posts. After all I’ll be subscribing for your feed and I am hoping you write again very soon!
-
PMI's U.S. launch of flagship IQOS device needs FDA green light
*
Six health campaign groups wrote letter to FDA criticising PMI Say PMI misrepresented past FDA decisions
on IQOS
*
PMI says it discusses its products in accordance with law
*
FDA acknowledges receiving campaigners' letter
By Emma Rumney
LONDON, July 16 (Reuters) - Health campaigners have written to
U.S. regulators accusing Philip Morris International of misrepresenting past regulatory decisions, seeking to disrupt the launch of its flagship heated tobacco device IQOS in the United States.
The world's biggest tobacco company by market value has spent billions of dollars
developing the product, which investors see as key to driving future growth.
But it needs permission from the U.S. Food and Drug Administration to sell it in the world's second largest tobacco market by
revenue.
Six anti-tobacco and health groups, including the Campaign for Tobacco-Free Kids, the American Academy
of Pediatrics and the American Lung Association, wrote to the
FDA to oppose IQOS-related applications PMI has submitted to the agency.
"PMI has repeatedly made misleading and deceptive statements wrongly suggesting that the FDA has found that IQOS reduces the risk of disease," the letter, dated June 27 and reviewed by Reuters,
said.
The campaign groups allege that PMI violated the FDA's
orders by suggesting IQOS offered lower risks than cigarettes.
Their letter cited four examples of such statements
in the United States, the Philippines, Mexico and Kazakhstan.
They also said in the letter that upcoming independent studies contradict
PMI's findings about how many IQOS users completely switch to the device from cigarettes.
Presentations on the studies from the International Tobacco Control Project
(ITC) at Canada's University of Waterloo are attached to the letter as exhibits.
They show the ITC found a far lower rate of IQOS users had quit smoking in Japan and Korea than estimates from PMI.
These factors "directly bear on whether PMI should be permitted to market IQOS" in the United States, the campaigners' letter said.
The contents of the letter have not been previously reported.
Asked by Reuters to respond to the letter, a PMI spokesperson said the company was proud to discuss the FDA's conclusions on IQOS.
The spokesperson did not address each example but said some of the
language flagged by campaigners was, in the company's view, compatible with
the FDA's orders.
"Wherever we discuss our science and our products, we do so in accordance with all applicable laws," the spokesperson said.
Reuters could not determine whether the campaigners' letter would change the FDA's
approach to IQOS. The agency said it had received the letter and would respond directly to
the senders. It did not comment further.
Devices like IQOS heat up sticks of ground tobacco without burning
them in an attempt to avoid the harmful chemicals released via combustion.
The FDA first authorised PMI to sell an older version of IQOS
in 2019. It subsequently authorised the company to market it as
offering reduced exposure to harmful chemicals versus cigarettes for smokers who completely switch - known as an "exposure modification order".
The FDA can also issue a "risk modification order", authorising a company to claim
its product reduces the risk of tobacco-related harm and disease.
But this is harder to prove, especially without long-term, epidemiological studies.
The FDA rejected PMI's previous application to say its older IQOS device results in reduced health risks,
saying there wasn't sufficient evidence to support this.
PMI applied in 2023 to renew its existing exposure modification orders.
Later that year, it also applied to sell and market a newer version of the IQOS device in the same way.
The FDA has yet to decide on these applications.
Marketing the product as having health benefits compared to traditional cigarettes could
help PMI persuade consumers to switch as well as afford it tax benefits versus cigarettes in some U.S.
states.
SWITCH RATES
The campaign groups also cited preliminary data from ITC studies in Japan and Korea, saying it contradicted
PMI's findings about how many IQOS users completely switch from cigarettes.
The studies have been presented at academic conferences but have
not yet been submitted for publication in a journal,
ITC researchers told Reuters. As a result, study abstracts have been peer reviewed but the full findings have yet to
go through that process.
Japan is IQOS' largest market and the introduction of heated
tobacco there coincided with an accelerated decline in cigarette sales.
PMI estimates more than seven out of 10 of its registered IQOS customers globally have quit
cigarettes. A 2023 PMI application to the FDA emphasised that the majority of IQOS users were using IQOS exclusively.
However, the ITC's researchers put the percentage of all IQOS users that had quit smoking
at just 15% in Japan and 30% in Korea in 2021.
Users most commonly used IQOS and cigarettes simultaneously, known as "dual use", often leading to an overall increase
in tobacco consumption, the ITC researchers found.
PMI pointed to a 2019 Japanese government health survey,
where 75% of respondents who reported using heated tobacco said they did not smoke.
However, a paper published this year, led by researchers
from Georgetown University, highlighted flaws in the government's survey, including changes to
the question format that can lead to under-reporting of smoking.
Other surveys have also found higher rates of dual use than the government,
it said.
(Reporting by Emma Rumney; Editing by Matt Scuffham and
Emelia Sithole-Matarise) -
Hi! I could have sworn I've been to this blog before but after looking at a
few of the posts I realized it's new to me.
Anyways, I'm certainly pleased I found it and I'll be bookmarking it and checking back often! -
Good blog post. I definitely love this site. Keep writing!
-
We absolutely love your blog and find most of your post's to be
precisely what I'm looking for. Would you offer guest writers to write content
available for you? I wouldn't mind producing a post or elaborating on a few of the subjects you write
concerning here. Again, awesome site! -
Hello! Quick question that's entirely off topic.
Do you know how to make your site mobile friendly? My blog looks weird when browsing from my
iphone. I'm trying to find a template or plugin that might be
able to fix this problem. If you have any suggestions, please
share. Appreciate it! -
My spouse and I stumbled over here from a different web page and thought
I might check things out. I like what I see so i am
just following you. Look forward to looking into your web page for a second time. -
Does your site have a contact page? I'm having problems locating it
but, I'd like to send you an email. I've got some creative ideas for
your blog you might be interested in hearing.
Either way, great site and I look forward to seeing it improve
over time.